Market Overview

UPDATE: Goldman Sachs Initiates Genomic Health at Neutral on Limited Upside

Share:
Related GHDX
Genomic Health's Oncotype DX® Prostate Cancer Test Receives Medicare Coverage
2 Small Cap Pharma Stocks Credit Suisse Loves

Goldman Sachs initiated coverage on Genomic Health (NASDAQ: GHDX) with a Neutral rating and a $36 price target.

Goldman Sachs commented, "Our thesis is based on (1) growth potential from new product cycles offset by (2) underappreciated market development costs and (3) mounting competition and an uncertain regulatory environment. How we are different: Our proprietary analysis of GHDX's new products and the regulatory landscape suggests these new tests may improve on the standard of care but face material uncertainties that are not yet fully appreciated by the Street."

Genomic Health closed at $33.77 on Wednesday.

Latest Ratings for GHDX

DateFirmActionFromTo
Aug 2015Raymond JamesUpgradesUnderperformMarket Perform
Aug 2015Canaccord GenuityMaintainsHold
May 2015JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for GHDX
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (GHDX)

Get Benzinga's Newsletters